Vonsetamig

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Antibody MediatedChronic Kidney Disease (CKD)Lupus Nephritis (LN)Plasma Cell Mediated

Phase 1

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

Active, not recruitingNCT05092347

Regeneron PharmaceuticalsChronic Kidney Disease (CKD)

Start: 2022-08-02End: 2027-11-22Updated: 2026-06-02

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

RecruitingNCT06975787

Regeneron PharmaceuticalsLupus Nephritis (LN)

Start: 2025-12-22End: 2029-09-10Target: 90Updated: 2026-09-14

Unknown Phase

Compassionate Use of Vonsetamig

Regeneron PharmaceuticalsAntibody Mediated, Plasma Cell Mediated

Updated: 2026-08-21

Related Papers

Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies

Cell Reports Medicine2023-12-0120 citations